Patents by Inventor Elmar Kraus

Elmar Kraus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF
    Publication number: 20170081418
    Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.
    Type: Application
    Filed: June 18, 2016
    Publication date: March 23, 2017
    Inventors: Elmar KRAUS, Christoph BRUECHER, Benjamin DAELKEN, Steffen ZENG, Frank OSTERROTH, Christoph UHEREK, Silke AIGNER, Matthias GERMER, Gregor SCHULZ, Thomas HAEDER
  • Method for treating psoriasis
    Patent number: 9550831
    Abstract: The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: January 24, 2017
    Assignee: BIOTEST AG
    Inventors: Silke Aigner, Matthias Germer, Frank Osterroth, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken, Gregor Schulz
  • Agent for treating disease
    Patent number: 9512226
    Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: December 6, 2016
    Assignee: BIOTEST AG
    Inventors: Matthias Germer, Frank Osterroth, Silke Aigner, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken, Gregor Schulz
  • Immunoconjugates targeting CD138 and uses thereof
    Patent number: 9387261
    Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: July 12, 2016
    Assignees: BIOTEST AG, IMMUNOGEN INC.
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Matthias Germer, Gregor Schulz, Thomas Haeder
  • AGENTS TARGETING CD138 AND USES THEREOF
    Publication number: 20160185854
    Abstract: Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells.
    Type: Application
    Filed: July 29, 2015
    Publication date: June 30, 2016
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Silke Aigner, Gregor Schulz, Christoph Uherek
  • Method for treating psoriasis
    Patent number: 9334325
    Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: May 10, 2016
    Assignee: BIOTEST AG
    Inventors: Frank Osterroth, Silke Aigner, Matthias Germer, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken
  • Agents targeting CD138 and uses thereof
    Patent number: 9221914
    Abstract: Disclosed is a human murine chimeric antibody targeting CD138 which substantially retains the antigen binding region of its murine counterpart. The engineered antibody displays improved binding affinities to the antigen and/or more homogenous binding to target cells relative to its murine counterpart. A constant region of the immunoglobulin heavy chain is preferably an IgG4 isotype constant region.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: December 29, 2015
    Assignee: BIOTEST AG
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Gregor Schulz
  • Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
    Patent number: 9011864
    Abstract: Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and kits allow appropriate sequestration of non-target cells while maintaining a high degree of effectiveness of the immunoconjugates against target cells.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: April 21, 2015
    Assignees: Biotest AG, Immunogen, Inc.
    Inventors: Gregor Schulz, Christoph Bruecher, Frank Osterroth, Steffen Zeng, Christoph Uherek, Silke Aigner, Benjamin Daelken, Markus Ruehle, Elmar Kraus
  • Conjugates of hydroxyalkyl starch and a protein
    Patent number: 8840879
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: September 23, 2014
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • Conjugates of hydroxyalkyl starch and a protein
    Patent number: 8017739
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: September 13, 2011
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • CONJUGATES OF HYDROXYALKYL STARCH AND A PROTEIN
    Publication number: 20110200555
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Application
    Filed: February 1, 2011
    Publication date: August 18, 2011
    Applicant: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • AGENT FOR TREATING DISEASE
    Publication number: 20110059084
    Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg.
    Type: Application
    Filed: September 13, 2010
    Publication date: March 10, 2011
    Inventors: FRANK OSTERROTH, SILKE AIGNER, MATTHIAS GERMER, CHRISTOPH UHEREK, ELMAR KRAUS, ANDREA WARTENBERG-DEMAND, DANIELE WOLF, SIBYLLE KAISER, JUERGEN LINDNER, CHRISTOPH BRUECHER, BENJAMIN DAELKEN
  • AGENT FOR TREATING DISEASE
    Publication number: 20110059082
    Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.
    Type: Application
    Filed: September 13, 2010
    Publication date: March 10, 2011
    Inventors: Matthias Germer, Frank Osterroth, Silke Aigner, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken
  • AGENT FOR TREATING DISEASE
    Publication number: 20110059083
    Abstract: The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.
    Type: Application
    Filed: September 13, 2010
    Publication date: March 10, 2011
    Inventors: SILKE AIGNER, MATTHIAS GERMER, FRANK OSTERROTH, CHRISTOPH UHEREK, ELMAR KRAUS, ANDREA WARTENBERG-DEMAND, DANIELE WOLF, SIBYLLE KAISER, JUERGEN LINDNER, CHRISTOPH BRUECHER, BENJAMIN DAELKEN
  • IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF
    Publication number: 20090232810
    Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.
    Type: Application
    Filed: December 23, 2008
    Publication date: September 17, 2009
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Matthias Germer
  • METHOD OF DECREASING CYTOTOXIC SIDE-EFFECTS AND IMPROVING EFFICACY OF IMMUNOCONJUGATES
    Publication number: 20090181038
    Abstract: Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and kits allow appropriate sequestration of non-target cells while maintaining a high degree of effectiveness of the immunoconjugates against target cells.
    Type: Application
    Filed: December 23, 2008
    Publication date: July 16, 2009
    Inventors: Gregor Schulz, Christoph Bruecher, Frank Osterroth, Steffen Zeng, Christoph Uherek, Silke Aigner, Benjamin Daelken, Markus Ruehle, Elmar Kraus
  • AGENTS TARGETING CD138 AND USES THEREOF
    Publication number: 20090175863
    Abstract: Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells.
    Type: Application
    Filed: December 23, 2008
    Publication date: July 9, 2009
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner
  • Conjugates of hydroxyalkyl starch and a protein
    Publication number: 20090047251
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Application
    Filed: September 8, 2006
    Publication date: February 19, 2009
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • Use of recombinant albumin in dialysis after liver failure
    Publication number: 20040217055
    Abstract: The present invention relates to the use of recombinant HSA in dialysis, wherein the recombinant HSA has been purified from accompanying fatty acids during its production.
    Type: Application
    Filed: March 10, 2004
    Publication date: November 4, 2004
    Inventors: Elmar Kraus, Wolfram Eichner